Neurocysticercosis: An Update

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Neurocysticercosis (NCC) is the most common helminthic disease of the nervous system in humans and a major cause of acquired epilepsy worldwide. The presentation of the disease is dependent on both the immunological response of the host against the parasite as well as the location of the encysted organisms within the central nervous system (CNS). The principles of management utilized for intraparenchymal disease cannot be applied to extraparenchymal NCC. An advance in management of intraparenchymal NCC, the most common form encountered by physicians, is the use of both albendazole and praziquantel as a treatment strategy. Patients with subarachnoid NCC (SANCC) require months of treatment with both an antiparasitic agent and steroids to avoid complications such as hydrocephalus and vascular events during treatment. The determinants of successful treatment in SANCC have not been established, but response to therapy can be determined by evaluating several endpoints related to disease evolution including radiographic changes, serum antigen, and CSF antigen. Intraventricular NCC is primarily a surgical disease and data supports minimally invasive endoscopic removal of cysts in many of these patients. NCC is increasingly recognized in non-endemic countries due to increased immigration making it important for physicians to become familiar with the management of this disease.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalCurrent Infectious Disease Reports
Volume16
Issue number11
DOIs
StatePublished - Oct 23 2014

Fingerprint

Neurocysticercosis
Physicians
Therapeutics
Antigens
Antiparasitic Agents
Praziquantel
Albendazole
Emigration and Immigration
Hydrocephalus
Disease Management
Nervous System Diseases
Blood Vessels
Cysts
Epilepsy
Parasites
Central Nervous System
Steroids
Serum

Keywords

  • Central nervous system infection
  • Cysticercosis
  • Helminthic infection
  • Hydrocephalus
  • Neurocysticercosis
  • Taenia solium
  • Tapeworm infection

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Neurocysticercosis : An Update. / Coyle, Christina M.

In: Current Infectious Disease Reports, Vol. 16, No. 11, 23.10.2014, p. 1-9.

Research output: Contribution to journalArticle

@article{f373b56f2a24494595bccbf93f911749,
title = "Neurocysticercosis: An Update",
abstract = "Neurocysticercosis (NCC) is the most common helminthic disease of the nervous system in humans and a major cause of acquired epilepsy worldwide. The presentation of the disease is dependent on both the immunological response of the host against the parasite as well as the location of the encysted organisms within the central nervous system (CNS). The principles of management utilized for intraparenchymal disease cannot be applied to extraparenchymal NCC. An advance in management of intraparenchymal NCC, the most common form encountered by physicians, is the use of both albendazole and praziquantel as a treatment strategy. Patients with subarachnoid NCC (SANCC) require months of treatment with both an antiparasitic agent and steroids to avoid complications such as hydrocephalus and vascular events during treatment. The determinants of successful treatment in SANCC have not been established, but response to therapy can be determined by evaluating several endpoints related to disease evolution including radiographic changes, serum antigen, and CSF antigen. Intraventricular NCC is primarily a surgical disease and data supports minimally invasive endoscopic removal of cysts in many of these patients. NCC is increasingly recognized in non-endemic countries due to increased immigration making it important for physicians to become familiar with the management of this disease.",
keywords = "Central nervous system infection, Cysticercosis, Helminthic infection, Hydrocephalus, Neurocysticercosis, Taenia solium, Tapeworm infection",
author = "Coyle, {Christina M.}",
year = "2014",
month = "10",
day = "23",
doi = "10.1007/s11908-014-0437-6",
language = "English (US)",
volume = "16",
pages = "1--9",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Neurocysticercosis

T2 - An Update

AU - Coyle, Christina M.

PY - 2014/10/23

Y1 - 2014/10/23

N2 - Neurocysticercosis (NCC) is the most common helminthic disease of the nervous system in humans and a major cause of acquired epilepsy worldwide. The presentation of the disease is dependent on both the immunological response of the host against the parasite as well as the location of the encysted organisms within the central nervous system (CNS). The principles of management utilized for intraparenchymal disease cannot be applied to extraparenchymal NCC. An advance in management of intraparenchymal NCC, the most common form encountered by physicians, is the use of both albendazole and praziquantel as a treatment strategy. Patients with subarachnoid NCC (SANCC) require months of treatment with both an antiparasitic agent and steroids to avoid complications such as hydrocephalus and vascular events during treatment. The determinants of successful treatment in SANCC have not been established, but response to therapy can be determined by evaluating several endpoints related to disease evolution including radiographic changes, serum antigen, and CSF antigen. Intraventricular NCC is primarily a surgical disease and data supports minimally invasive endoscopic removal of cysts in many of these patients. NCC is increasingly recognized in non-endemic countries due to increased immigration making it important for physicians to become familiar with the management of this disease.

AB - Neurocysticercosis (NCC) is the most common helminthic disease of the nervous system in humans and a major cause of acquired epilepsy worldwide. The presentation of the disease is dependent on both the immunological response of the host against the parasite as well as the location of the encysted organisms within the central nervous system (CNS). The principles of management utilized for intraparenchymal disease cannot be applied to extraparenchymal NCC. An advance in management of intraparenchymal NCC, the most common form encountered by physicians, is the use of both albendazole and praziquantel as a treatment strategy. Patients with subarachnoid NCC (SANCC) require months of treatment with both an antiparasitic agent and steroids to avoid complications such as hydrocephalus and vascular events during treatment. The determinants of successful treatment in SANCC have not been established, but response to therapy can be determined by evaluating several endpoints related to disease evolution including radiographic changes, serum antigen, and CSF antigen. Intraventricular NCC is primarily a surgical disease and data supports minimally invasive endoscopic removal of cysts in many of these patients. NCC is increasingly recognized in non-endemic countries due to increased immigration making it important for physicians to become familiar with the management of this disease.

KW - Central nervous system infection

KW - Cysticercosis

KW - Helminthic infection

KW - Hydrocephalus

KW - Neurocysticercosis

KW - Taenia solium

KW - Tapeworm infection

UR - http://www.scopus.com/inward/record.url?scp=84910660222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910660222&partnerID=8YFLogxK

U2 - 10.1007/s11908-014-0437-6

DO - 10.1007/s11908-014-0437-6

M3 - Article

AN - SCOPUS:84910660222

VL - 16

SP - 1

EP - 9

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 11

ER -